Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intranasal Midazolam Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

NCT01999777
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement

NCT01188551
View directory record Official record
Conditions
Chronic Otitis Media
Interventions
Dexmedetomidine, Fentanyl, Midazolam
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 20, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

NCT01529034
View directory record Official record
Conditions
Epilepsy
Interventions
USL261
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department

NCT03085563
View directory record Official record
Conditions
Conscious Sedation, Simple Lacerations Less Than 4 cm, Lumbar Punctures, Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement
Interventions
Nitrous Oxide, Midazolam
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair

NCT02168439
View directory record Official record
Conditions
Laceration, Anxiety
Interventions
Dexmedetomidine, Midazolam
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Year to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 20, 2026, 8:08 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED

NCT05934669
View directory record Official record
Conditions
Laceration of Skin, Anxiety, Discharge Time
Interventions
Intranasal Midazolam, Intranasal Dexmedetomidine, Intranasal Ketamine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 5 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 20, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

NCT02161185
View directory record Official record
Conditions
Epilepsy
Interventions
USL261
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Fresno, California • Ventura, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2

NCT02356705
View directory record Official record
Conditions
Sedation
Interventions
Midazolam, xylocaine, saline placebo
Drug
Lead sponsor
Jennifer Victory, RN, CCRC
Other
Eligibility
18 Months to 7 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 20, 2026, 8:08 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Intranasal Dexmedetomidine

NCT02985697
View directory record Official record
Conditions
Safety and Efficacy of Intranasal Dexmedetomidine
Interventions
Dexmedetomidine, Midazolam Hydrochloride, Nitrous Oxide
Drug
Lead sponsor
Bon Secours Pediatric Dental Associates
Other
Eligibility
3 Years to 6 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Midazolam in Children as a Pre-Operative Sedative

NCT02314546
View directory record Official record
Conditions
Sedation, Conscious
Interventions
Midazolam, xylocaine, saline placebo
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Months to 7 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D

NCT02635282
View directory record Official record
Conditions
Abscess, Pain
Interventions
intranasal ketamine, intranasal fentanyl, intranasal midazolam
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
3 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 20, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 8:08 PM EDT
Not listed Phase 4 Interventional

Nitrous Oxide Prior to Intranasal Midazolam for Moderate Dental Sedation in Pediatric Patients

NCT04083105
View directory record Official record
Conditions
Dental Anxiety, Pain
Interventions
Nitrous Oxide, Midazolam
Drug
Lead sponsor
Children's Hospital Colorado
Other
Eligibility
3 Years to 8 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 20, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional

Pediatric Dose Optimization for Seizures in Emergency Medical Services

NCT05121324
View directory record Official record
Conditions
Seizures
Interventions
Standardized seizure protocol, Conventional seizure protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 13 Years
Enrollment
6,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

Intranasal Dexmedetomidine Premedication in Children

NCT02250703
View directory record Official record
Conditions
Preoperative Sedation
Interventions
Midazolam, Dexmedetomidine
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
5 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 20, 2026, 8:08 PM EDT
Terminated Phase 4 Interventional Results available

IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair

NCT03528512
View directory record Official record
Conditions
Laceration of Skin
Interventions
Ketamine, Midazolam and fentanyl
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
6 Months to 10 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available

Volumes of Administration for Intranasal Midazolam

NCT01948908
View directory record Official record
Conditions
Children Requiring Sedation to Facilitate Laceration Repair
Interventions
Intranasal midazolam
Drug
Lead sponsor
Columbia University
Other
Eligibility
1 Year to 7 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 20, 2026, 8:08 PM EDT
Terminated Phase 4 Interventional

Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients

NCT03043430
View directory record Official record
Conditions
Anxiety, Pediatric ALL, Procedural Anxiety
Interventions
Ketamine 100 MG/ML, Midazolam 5 MG/ML
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
2 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 20, 2026, 8:08 PM EDT
Recruiting Not applicable Interventional

Improving Status Epilepticus Treatment Times

NCT06194747
View directory record Official record
Conditions
Status Epilepticus
Interventions
Quality improvement bundle, Quality improvement bundle and local PDSA cycles with central support, Quality improvement bundle and local PDSA cycles without central support
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
30 Days to 18 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 20, 2026, 8:08 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD

NCT02206776
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Intranasal Ketamine, Intranasal Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

NCT01390220
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 20, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children

NCT04586504
View directory record Official record
Conditions
Procedural Anxiety
Interventions
Intranasal midazolam
Drug
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 7 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 20, 2026, 8:08 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room

NCT05057689
View directory record Official record
Conditions
Acute Stress Disorder, Anxiety, Pain
Interventions
Intranasal Dexmedetomidine (4 mcg/kg), Intranasal Fentanyl (2 mcg/kg), Intranasal Midazolam (5 mg/kg)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 6 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 20, 2026, 8:08 PM EDT